AUTHOR=Chen Ke-Guang , Zhang Ye-Hui , Ye Pan-Pan , Gao Xue-Hu , Song Lin-Lin , Zhou Hai-Yan , Li Qian , Zhao Fu-Rong , Shi Jin-Yi , Yang Xin-Mei , Shen Kai , Feng Sheng , Zhao Wei 

TITLE=Pharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1294810

DOI=10.3389/fphar.2023.1294810

ISSN=1663-9812

ABSTRACT=INS068 is a novel, soluble, and long-acting insulin analog. In this study, we evaluated the pharmacokinetics and relative bioavailability of two formulations of INS068 in healthy Chinese subjects: a reference formulation packaged in vials and administered via syringe (R), and a test formulation packaged and administered via pen injector (T). A randomized, open-label, two-period, two-sequence crossover study was conducted with 24 healthy Chinese subjects. Subjects were randomized and administered subcutaneously in the abdomen at 0.4 U/kg of test or reference INS068 injection according to an open crossover design. INS068 concentrations in the serum were measured using LC-MS/MS, and the pharmacokinetic parameters of maximum concentration (Cmax) and area under the concentration-time curve (AUC0-t and AUC0-∞) were used to evaluate relative bioavailability. After a single dose at 0.4 U/kg, the median Tmax of INS068was 12 h for both formulations, and the mean t1/2 for T and R was 13.0 h and 12.6 h, respectively.The geometric means of Cmax and AUC0-∞ were 3.99 nmol/L and 120 h•nmol/L for the T, and 4.05 nmol/L and 117 h•nmol/L for the R, respectively. The geometric mean ratios of Cmax, AUC0-t and AUC0-∞ of T over R were 98.7% (90% CI: 92.7% -105.2%), 102.6% (90% CI: 100.0% -105.3%) and 102.8% (90% CI: 100.1% -105.5%). The overall PK profile of the two formulations of INS068 injection was comparable in healthy subjects, and the pen injector of INS068 had adequate safety and tolerability, supporting it as a new formulation in a phase III study and bridging PK data from early phase clinical trials.ClinicalTrials.gov identifier: NCT05336071